Olodaterol

Summary

Olodaterol (CHEMBL605846) is an approved small-molecule β-adrenergic agonist (ATC R03AC19) targeting ADRB2; indicated across 4 conditions including obstructive lung disease and chronic obstructive pulmonary disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R03AC19
• Targets: 1 (ADRB2)
• Indications: 4 conditions
• Clinical trials: 47
• Chemistry: 386.4 Da · C21H26N2O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL605846
Name	Olodaterol
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	11504295
ChEBI	CHEBI:82700
ATC	R03AC19
Molecular formula	C21H26N2O5
Molecular weight	386.4
InChIKey	COUYJEVMBVSIHV-SFHVURJKSA-N

SMILES: CC(C)(CC1=CC=C(C=C1)OC)NC[C@@H](C2=C3C(=CC(=C2)O)NC(=O)CO3)O

IUPAC name: 6-hydroxy-8-[(1R)-1-hydroxy-2-[[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino]ethyl]-4H-1,4-benzoxazin-3-one

ChEBI definition: A member of the class of benzoxazine that is 6-hydroxy-1,4-benzoxazin-3-one in which the hydrogen at position 4 is replaced by a (1R)-1-hydroxy-2-{[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino}ethyl group. Used (as its hydrochloride salt) for long-term treatment of airflow obstruction in patients with chronic obstructive pulmonary disease including chronic bronchitis and/or emphysema.

Pharmacological roles (ChEBI): β-adrenergic agonist, bronchodilator agent.

Also known as: BI 1744, BI-1744, Olodaterol, Striverdi respimat, OLODATEROL, olodaterol

Parent form; salt/anhydrous children: CHEMBL2105743

Patent coverage: 553 distinct patent families (1,404 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,297 (92%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ADRB2	β2-adrenoceptor	Agonist	10	0.4%	P07550

Broader ChEMBL bioactivity targets: 14 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, Beta-2 adrenergic receptor, Muscarinic acetylcholine receptor M2, Beta-1 adrenergic receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Prostaglandin G/H synthase 2, Sodium-dependent dopamine transporter, Voltage-gated inwardly rectifying potassium channel KCNH2, 3’,5’-cyclic-AMP phosphodiesterase 4D, Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 13 potent at pChembl ≥ 5 of 19 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADRB2	10.7	EC50	0.02	nM	CHEMBL_ACT_23194861
ADRB2	10.26	EC50	0.05	nM	CHEMBL_ACT_25928968
ADRB2	10.06	EC50	0.09	nM	CHEMBL_ACT_23306536
ADRB2	8.77	AC50	1.7	nM	CHEMBL_ACT_25233584
ADRB1	7.47	EC50	33.88	nM	CHEMBL_ACT_25929012
ADRA1A	7.26	AC50	55	nM	CHEMBL_ACT_25218071
SLC6A4	7.22	AC50	60.8	nM	CHEMBL_ACT_25150335
ADRB1	6.91	EC50	123	nM	CHEMBL_ACT_23306497
ADRB1	6.24	AC50	580	nM	CHEMBL_ACT_25121776
CHRM2	5.29	AC50	5100	nM	CHEMBL_ACT_25213741
KCNH2	5.2	AC50	6300	nM	CHEMBL_ACT_25117866
HTR2B	5.18	AC50	6648	nM	CHEMBL_ACT_25227524
ADRA2A	5	AC50	10000	nM	CHEMBL_ACT_25219895

Target pathways

Aggregated over 1 target gene(s): ADRB2.

Top Reactome pathways

16 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	1	ADRB2
Membrane Trafficking	1	ADRB2
Signaling by GPCR	1	ADRB2
Class A/1 (Rhodopsin-like receptors)	1	ADRB2
Amine ligand-binding receptors	1	ADRB2
GPCR downstream signalling	1	ADRB2
Adrenoceptors	1	ADRB2
Metabolism of proteins	1	ADRB2
G alpha (s) signalling events	1	ADRB2
GPCR ligand binding	1	ADRB2
Vesicle-mediated transport	1	ADRB2
Deubiquitination	1	ADRB2
Ub-specific processing proteases	1	ADRB2
Post-translational protein modification	1	ADRB2
Cargo recognition for clathrin-mediated endocytosis	1	ADRB2
Clathrin-mediated endocytosis	1	ADRB2

Dominant GO biological processes

GO term	Targets
diet induced thermogenesis	1
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure	1
regulation of sodium ion transport	1
transcription by RNA polymerase II	1
receptor-mediated endocytosis	1
smooth muscle contraction	1
cell surface receptor signaling pathway	1
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	1
endosome to lysosome transport	1
response to cold	1
positive regulation of cardiac muscle cell apoptotic process	1
negative regulation of cardiac muscle cell apoptotic process	1
positive regulation of bone mineralization	1
heat generation	1
negative regulation of multicellular organism growth	1

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
obstructive lung disease	4	MONDO:0002267	HP:0006536

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
chronic obstructive pulmonary disease	3	MONDO:0005002	EFO:0000341
asthma	2	MONDO:0004979	MONDO:0004979
liver disorder	1	MONDO:0005154	EFO:0001421

Clinical trials

Total trials: 47.

Phase distribution

Phase	Trials
PHASE3	20
Not specified	11
PHASE4	8
PHASE1	5
PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02682862	PHASE4	COMPLETED	Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics
NCT02683109	PHASE4	COMPLETED	Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD
NCT02853123	PHASE4	COMPLETED	Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
NCT03055988	PHASE4	COMPLETED	Cardiovascular Function in COPD Patients
NCT03152149	PHASE4	COMPLETED	INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol
NCT03240575	PHASE4	COMPLETED	The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus
NCT03425617	PHASE4	COMPLETED	Effects of Dual Bronchodilator Treatment on Cardiopulmonary Interactions in COPD
NCT04223843	PHASE4	COMPLETED	A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale
NCT00782210	PHASE3	COMPLETED	12 / 48 Week Pivotal PFT vs PBO in COPD I
NCT00931385	PHASE3	COMPLETED	Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
NCT01040689	PHASE3	COMPLETED	Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
NCT01040728	PHASE3	COMPLETED	A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
NCT01040793	PHASE3	COMPLETED	Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II
NCT01431274	PHASE3	COMPLETED	Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
NCT01431287	PHASE3	COMPLETED	Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
NCT01525615	PHASE3	COMPLETED	A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD
NCT01533922	PHASE3	COMPLETED	Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients
NCT01533935	PHASE3	COMPLETED	Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.
NCT01536262	PHASE3	COMPLETED	Japan Long-term Safety for Tiotropium Plus Olodaterol
NCT01559116	PHASE3	COMPLETED	Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
NCT01694771	PHASE3	COMPLETED	Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
NCT01696058	PHASE3	COMPLETED	Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
NCT01964352	PHASE3	COMPLETED	Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
NCT01969721	PHASE3	COMPLETED	Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients
NCT02006732	PHASE3	COMPLETED	Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
NCT02085161	PHASE3	COMPLETED	To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways
NCT02296138	PHASE3	COMPLETED	Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
NCT02629965	PHASE3	COMPLETED	Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients
NCT00928668	PHASE2	COMPLETED	Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma
NCT01428622	PHASE2	WITHDRAWN	Olodaterol Bridging Study in Asthma
NCT02030535	PHASE2	COMPLETED	Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers
NCT07267130	PHASE1	RECRUITING	A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects
NCT01153711	PHASE1	COMPLETED	Relative Bioavailability of of Olodaterol and Ketoconazole
NCT01153724	PHASE1	COMPLETED	Relative Bioavailability of Olodaterol and Fluconazole
NCT01703845	PHASE1	COMPLETED	A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.
NCT02969317	PHASE1	COMPLETED	Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients
NCT03030638	Not specified	COMPLETED	Drug Utilization Study for Olodaterol
NCT03979807	Not specified	COMPLETED	A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT04011475	Not specified	COMPLETED	A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment
NCT04138758	Not specified	COMPLETED	Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS
NCT04249310	Not specified	COMPLETED	Early Intervention Efficacy in COPD
NCT04926233	Not specified	COMPLETED	Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study
NCT04994574	Not specified	COMPLETED	Effects of Tiotropium/Olodaterol on Cardio-pulmonary Exercise Capacity in Patients With Hyperinflated Chronic Obstructive Pulmonary Disease [ACHIEVE]
NCT05127304	Not specified	COMPLETED	A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol
NCT05393245	Not specified	COMPLETED	Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
NCT05402020	Not specified	COMPLETED	Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
NCT07541378	Not specified	SUSPENDED	Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPD

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

188 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
DESLORATADINE	ChEMBL + PubChem	Phase 4 (approved)	ADRB2
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	ADRB2
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	ADRB2
ACEBUTOLOL	ChEMBL	Phase 4 (approved)	ADRB2
ADENOSINE	ChEMBL	Phase 4 (approved)	ADRB2
ALBUTEROL	ChEMBL	Phase 4 (approved)	ADRB2
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRB2
AMLODIPINE	ChEMBL	Phase 4 (approved)	ADRB2
AMOXAPINE	ChEMBL	Phase 4 (approved)	ADRB2
ARFORMOTEROL	ChEMBL	Phase 4 (approved)	ADRB2
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRB2
ATENOLOL	ChEMBL	Phase 4 (approved)	ADRB2
BENPERIDOL	ChEMBL	Phase 4 (approved)	ADRB2
BETAXOLOL	ChEMBL	Phase 4 (approved)	ADRB2
BISOPROLOL	ChEMBL	Phase 4 (approved)	ADRB2
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRB2
BROMOCRIPTINE	ChEMBL	Phase 4 (approved)	ADRB2
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	ADRB2
CARTEOLOL	ChEMBL	Phase 4 (approved)	ADRB2
CARVEDILOL	ChEMBL	Phase 4 (approved)	ADRB2
CELIPROLOL	ChEMBL	Phase 4 (approved)	ADRB2
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	ADRB2
CLEMASTINE	ChEMBL	Phase 4 (approved)	ADRB2
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	ADRB2
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	ADRB2
CLOZAPINE	ChEMBL	Phase 4 (approved)	ADRB2
DARIFENACIN	ChEMBL	Phase 4 (approved)	ADRB2
DEXAMETHASONE	ChEMBL	Phase 4 (approved)	ADRB2
DIPIVEFRIN	ChEMBL	Phase 4 (approved)	ADRB2
DOBUTAMINE	ChEMBL	Phase 4 (approved)	ADRB2
DOMPERIDONE	ChEMBL	Phase 4 (approved)	ADRB2
DOPAMINE	ChEMBL	Phase 4 (approved)	ADRB2
DOXAZOSIN	ChEMBL	Phase 4 (approved)	ADRB2
ELAGOLIX	ChEMBL	Phase 4 (approved)	ADRB2
EPINEPHRINE	ChEMBL	Phase 4 (approved)	ADRB2
EPINEPHRINE BITARTRATE	ChEMBL	Phase 4 (approved)	ADRB2
ERGOTAMINE	ChEMBL	Phase 4 (approved)	ADRB2
ESMOLOL	ChEMBL	Phase 4 (approved)	ADRB2
FENOTEROL	ChEMBL	Phase 4 (approved)	ADRB2
FLUSPIRILENE	ChEMBL	Phase 4 (approved)	ADRB2
FORMOTEROL	ChEMBL	Phase 4 (approved)	ADRB2
HALOPERIDOL	ChEMBL	Phase 4 (approved)	ADRB2
INDACATEROL	ChEMBL	Phase 4 (approved)	ADRB2
ISOETHARINE	ChEMBL	Phase 4 (approved)	ADRB2
ISOPROTERENOL	ChEMBL	Phase 4 (approved)	ADRB2
LABETALOL	ChEMBL	Phase 4 (approved)	ADRB2
LEVOBUNOLOL	ChEMBL	Phase 4 (approved)	ADRB2
LEVOSALBUTAMOL	ChEMBL	Phase 4 (approved)	ADRB2
LOFEPRAMINE	ChEMBL	Phase 4 (approved)	ADRB2
LOPERAMIDE	ChEMBL	Phase 4 (approved)	ADRB2
LOXAPINE	ChEMBL	Phase 4 (approved)	ADRB2
MEBEVERINE	ChEMBL	Phase 4 (approved)	ADRB2
METAPROTERENOL	ChEMBL	Phase 4 (approved)	ADRB2
METOPROLOL	ChEMBL	Phase 4 (approved)	ADRB2
MIFEPRISTONE	ChEMBL	Phase 4 (approved)	ADRB2
MONTELUKAST	ChEMBL	Phase 4 (approved)	ADRB2
NADOLOL	ChEMBL	Phase 4 (approved)	ADRB2
NEBIVOLOL	ChEMBL	Phase 4 (approved)	ADRB2
NITAZOXANIDE	ChEMBL	Phase 4 (approved)	ADRB2
NOREPINEPHRINE	ChEMBL	Phase 4 (approved)	ADRB2
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRB2
OLANZAPINE	ChEMBL	Phase 4 (approved)	ADRB2
OXPRENOLOL	ChEMBL	Phase 4 (approved)	ADRB2
PAROXETINE	ChEMBL	Phase 4 (approved)	ADRB2
PERPHENAZINE	ChEMBL	Phase 4 (approved)	ADRB2
PHENYLEPHRINE	ChEMBL	Phase 4 (approved)	ADRB2
PIMAVANSERIN	ChEMBL	Phase 4 (approved)	ADRB2
PIMOZIDE	ChEMBL	Phase 4 (approved)	ADRB2
PINDOLOL	ChEMBL	Phase 4 (approved)	ADRB2
PIPERACETAZINE	ChEMBL	Phase 4 (approved)	ADRB2
PRACTOLOL	ChEMBL	Phase 4 (approved)	ADRB2
PRENYLAMINE	ChEMBL	Phase 4 (approved)	ADRB2
PRIMAQUINE	ChEMBL	Phase 4 (approved)	ADRB2
PROMAZINE	ChEMBL	Phase 4 (approved)	ADRB2
PROPAFENONE	ChEMBL	Phase 4 (approved)	ADRB2
PROPRANOLOL	ChEMBL	Phase 4 (approved)	ADRB2
RANOLAZINE	ChEMBL	Phase 4 (approved)	ADRB2
REBOXETINE	ChEMBL	Phase 4 (approved)	ADRB2
RIBOFLAVIN 5’-PHOSPHATE	ChEMBL	Phase 4 (approved)	ADRB2
RIFAMPIN	ChEMBL	Phase 4 (approved)	ADRB2
RIFAXIMIN	ChEMBL	Phase 4 (approved)	ADRB2
RIMEGEPANT	ChEMBL	Phase 4 (approved)	ADRB2
RISPERIDONE	ChEMBL	Phase 4 (approved)	ADRB2
RITODRINE	ChEMBL	Phase 4 (approved)	ADRB2
SALMETEROL	ChEMBL	Phase 4 (approved)	ADRB2
SALMETEROL XINAFOATE	ChEMBL	Phase 4 (approved)	ADRB2
SILODOSIN	ChEMBL	Phase 4 (approved)	ADRB2
SOTALOL	ChEMBL	Phase 4 (approved)	ADRB2
SUNITINIB	ChEMBL	Phase 4 (approved)	ADRB2
TAMOXIFEN	ChEMBL	Phase 4 (approved)	ADRB2
TAMSULOSIN	ChEMBL	Phase 4 (approved)	ADRB2
TEGASEROD	ChEMBL	Phase 4 (approved)	ADRB2
TERBUTALINE	ChEMBL	Phase 4 (approved)	ADRB2
THIORIDAZINE	ChEMBL	Phase 4 (approved)	ADRB2
TIMOLOL	ChEMBL	Phase 4 (approved)	ADRB2
TIOCONAZOLE	ChEMBL	Phase 4 (approved)	ADRB2
TOLTERODINE	ChEMBL	Phase 4 (approved)	ADRB2
TOLVAPTAN	ChEMBL	Phase 4 (approved)	ADRB2
VALDECOXIB	ChEMBL	Phase 4 (approved)	ADRB2
VILANTEROL	ChEMBL	Phase 4 (approved)	ADRB2